-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Read: AstraZeneca and Kantar Bio have reached a licensing partnership to produce 100 million doses of the new crown vaccine this year! On August 6, Kantar Bio announced that it has signed an exclusive framework agreement with AstraZeneca for exclusive licensing cooperation with a Chinese mainland market to actively promote the development, production, supply and commercialization of adenovirus vector NEW crown edifice AZD122 in the Chinese mainland market through technology transfer.
future, the two sides will continue to explore the possibility of cooperation between the vaccine in other regions and markets.
under the terms of the cooperation framework agreement, Kantai Bio will ensure that by 2020 the annual production capacity of at least 100 million doses of the new coronavaccineated vaccine AZD1222 is reached, and by the end of 2021 the vaccine design capacity will be expanded to at least 200 million doses per year to meet the demand in the Chinese market.
in May this year, AstraZeneca established a partnership with Oxford University to develop, produce and supply the new crown vaccine AZD1222 globally, a landmark initiative.
AstraZeneca has pledged to provide more than 2 billion doses of the new vaccine.
at the same time, the company is establishing multiple supply chains with partners around the world to ensure a wide and equitable supply of vaccines to as many countries as possible around the world.
the interim results of the Phase I/II COV001 clinical trial, published recently in the top medical journal The Lancet, showed that the vaccine was resistant to and produced a robust immune response to the SARS-CoV-2 virus in all subjects assessed.
currently, Phase II/III clinical trials of the vaccine are being conducted in several countries around the world and are planned to be conducted in more regions to verify the effectiveness of the vaccine in protecting people from the new coronavirus infection and to test the safety and immune response of different ages and doses.
so far, AstraZeneca has entered into cooperation agreements with several countries and organizations around the world.
.
